Hangzhou Weice Biotechnology Co., Ltd. is a high-tech enterprise located in Linping District, Hangzhou. Since its establishment in August 2013, it has been specialized in the research and development, production and sales of POCT products. Weice Biotech has always adhered to the development concept of "making health management within reach", committed to building an ecological system of "chronic disease management + rapid diagnosis + digital medical care", and strived to become a globally trusted smart POCT provider.

Weice Biotechnology has established and maintained a quality management system that complies with the requirements of medical device production quality management specifications, the Appendix to the In vitro diagnostic reagents, (EN)ISO13485:2016, MDSAP includes the 21CFRPart820 requirements, and implements continuous measurement, analysis and Improvements to fully meet applicable regulations, standards and customer needs. At the same time, the product has been certified by many countries and regions such as China's NMPA, EU CE, and the US FDA.

Weice Bio has been deeply engaged in overseas markets and has strong advantages. Its products have been exported to more than 100 countries and regions including the United States, Italy, Germany, Turkey, etc., and have been widely recognized by local customers. It has established overseas subsidies in the United States, Hong Kong and India. company. In the Chinese market, Weice Bio products are sold to nearly 900 secondary and above hospitals.

Weice Biotech has strong technological research and development and innovation capabilities. The NB-IoT Internet of Things 5G blood glucose meter independently developed in January 2021 was successfully launched. Weice Bio attaches great importance to intellectual property protection and protects the company's intellectual property rights through trademark application, patent application and other means. At present, the company has hundreds of patents and software copyrights.